Company news
MannKind Corporation news in 2023
MannKind Corporation's news releases, calls and decks from 2023, newest first.
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
MannKind Corporation Reports 2023 Third Quarter Financial Results
November 6, 2023
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
November 5, 2023
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
October 30, 2023
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
October 29, 2023
MannKind Corporation Reports 2023 Second Quarter Financial Results
August 6, 2023
MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
July 31, 2023
MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
July 30, 2023
MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)
June 21, 2023
Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone
June 10, 2023
Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer
May 23, 2023
MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
May 9, 2023
Mannkind Corporation Reports 2023 First Quarter Financial Results
May 8, 2023
MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023
May 1, 2023
Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer
March 26, 2023
MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference
March 6, 2023
MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results
February 22, 2023
MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference
February 21, 2023
MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
February 15, 2023
Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference
February 9, 2023
MannKind Corporation to Participate in the Lytham Partners Investor Select Conference
January 23, 2023
MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease
January 22, 2023
MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference
January 4, 2023